Unjha Formul.

Which are the latest news on Unjha Formul.?

Why is Unjha Formulations Ltd falling/rising?

As of 05-Sep, Unjha Formulations Ltd's stock price is at Rs. 30.64, up 4.97%, supported by a strong bullish trend and significant investor interest, evidenced by a 510.34% increase in delivery volume. The stock has outperformed its sector and reached a new 52-week high, gaining for six consecutive days.

As of 05-Sep, Unjha Formulations Ltd's stock price is rising, currently at Rs. 30.64, reflecting an increase of Rs. 1.45 or 4.97%. This upward movement is supported by several factors. The stock has outperformed the sector by 5.42% today and has been on a positive trend, gaining for the last six consecutive days with a total return of 23.1% during this period. Additionally, the stock opened with a significant gain of 4.49% and reached a new 52-week high of Rs. 30.64.<BR><BR>Investor interest appears to be increasing, as evidenced by a substantial rise in delivery volume, which increased by 510.34% compared to the five-day average. Furthermore, the stock is trading above its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), indicating a strong bullish trend. Overall, these factors contribute to the stock's rising price.

Who are in the management team of Unjha Formul.?

The management team of Unjha Formul includes Krutiben M Patel (Managing Director), Jashodaben S Patel (Chairman), and several independent directors: Hasmukh C Chavda, Jitendrakumar Parshottamdas Limbachiya, and Mustufa Najmuddin, along with Company Secretary Jigar Ray and Additional Director Esham Patel.

The management team of Unjha Formul includes the following members:<BR><BR>1. **Krutiben M Patel** - Managing Director<BR>2. **Hasmukh C Chavda** - Independent Director<BR>3. **Jashodaben S Patel** - Chairman (Non-Executive)<BR>4. **Jitendrakumar Parshottamdas Limbachiya** - Independent Director<BR>5. **Jigar Ray** - Company Secretary & Compliance Officer<BR>6. **Mustufa Najmuddin** - Independent Director<BR>7. **Esham Patel** - Additional Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Unjha Formul. do?

Unjha Formulations Ltd is a micro-cap pharmaceutical company specializing in Isabgol (Psyllium) products, with a market cap of INR 12 Cr and reported net sales of 3 Cr for June 2026. Established in 1987, it has a P/E ratio of 26.00 and a return on equity of 12.50%.

Overview:<BR>Unjha Formulations Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of pharmaceutical formulations, particularly Isabgol (Psyllium) products.<BR><BR>History:<BR>Established in June 1987 as a partnership firm, Unjha Formulations has been a pioneer in Isabgol formulation. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 26.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.43<BR>- Return on Equity: 12.50%<BR>- Price to Book: 3.05<BR><BR>Contact Details:<BR>- Address: Khali Char Rasta, State Highway Ta Sidhpur Patan Gujarat : 384151<BR>- Tel: 91-2767-282395<BR>- Email: info@unjhaformulations.com<BR>- Website: http://www.unjhaformulations.com

Who are the peers of the Unjha Formul.?

Unjha Formul.'s peers include Dipna Pharmachem, Starsource Multi, Ortin Global, Beryl Drugs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Decipher Labs. Unjha Formul. has average management risk and a 1-year return of 10.70%, significantly outperforming Dipna Pharmachem, which has a return of -73.42%.

Peers: The peers of Unjha Formul. are Dipna Pharmachem, Starsource Multi, Ortin Global, Beryl Drugs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Decipher Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dipna Pharmachem, while Average management risk is found at Unjha Formul. and the rest. Below Average management risk is noted for Ortin Global, Beryl Drugs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Decipher Labs. Growth is Excellent at Dipna Pharmachem, Below Average at Unjha Formul. and the rest, and Average at Vivanza Biosci. Below Average growth is also seen in Ortin Global, Beryl Drugs, Ganga Pharma., and Brawn Biotech. Capital Structure is Good at Unjha Formul., while Below Average is noted for Dipna Pharmachem, Ortin Global, Beryl Drugs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Decipher Labs.<BR><BR>Return Snapshot: Unjha Formul. has a 1-year return of 10.70%, while Dipna Pharmachem has the lowest at -73.42%. Unjha Formul.'s return is significantly higher than that of Dipna Pharmachem. Additionally, the six-month returns are negative for Dipna Pharmachem, Starsource Multi, Vivanza Biosci., and Decipher Labs.

How big is Unjha Formul.?

As of 31st August, Unjha Formulations Ltd has a market capitalization of 12.00 Cr, with recent net sales of 15.29 Cr and a net profit of 0.48 Cr. Shareholder's funds are 3.84 Cr and total assets amount to 5.51 Cr as of March 2026.

As of 31st August, Unjha Formulations Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Unjha Formulations reported Net Sales of 15.29 Cr and a Net Profit of 0.48 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 3.84 Cr and Total Assets of 5.51 Cr.

Should I buy, sell or hold Unjha Formulations Ltd?

Are Unjha Formulations Ltd latest results good or bad?

Unjha Formulations Ltd's latest results show a return to profitability with a net profit of ₹0.16 crores, but revenue declined by 8.31% and operating margins contracted significantly, indicating ongoing challenges despite a positive stock reaction. Overall, the performance is more concerning than favorable.

Unjha Formulations Ltd's latest results present a mixed picture. On one hand, the company returned to profitability with a net profit of ₹0.16 crores in Q1 FY27, recovering from a loss of ₹0.74 crores in the previous quarter. This indicates a positive quarter-on-quarter recovery. However, year-on-year comparisons reveal a decline in revenue, which fell by 8.31% to ₹3.31 crores, and a significant contraction in operating margins from 11.63% to 6.04%. <BR><BR>The stock surged by 10.53% following the results, reflecting speculative enthusiasm rather than strong fundamentals. While the return on equity (ROE) of 18.49% suggests effective capital utilization, the overall financial performance is characterized by volatility and operational challenges. The decline in revenue and margins raises concerns about the company's ability to sustain growth in a competitive market.<BR><BR>In summary, while there are some positive indicators, the overall results suggest that Unjha Formulations is facing significant challenges, making the latest performance more concerning than favorable.

When is the next results date for Unjha Formulations Ltd?

Unjha Formulations Ltd will announce its results on 04 February 2026.

Unjha Formulations Ltd is scheduled to declare its results on 04 February 2026.

How has been the historical performance of Unjha Formul.?

Unjha Formul's historical performance has shown fluctuations in net sales and profits, with net sales decreasing to 13.86 Cr in March 2025 from 18.50 Cr in March 2024, but profit after tax increased to 0.41 Cr. Despite volatility, the company improved its profitability metrics and shareholder equity during this period.

Answer:<BR>The historical performance of Unjha Formul shows fluctuations in key financial metrics over the years, with notable changes in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Unjha Formul's net sales have varied significantly, reaching 13.86 Cr in March 2025, down from 18.50 Cr in March 2024, but up from 13.15 Cr in March 2023. The total operating income followed a similar trend, with a peak in March 2024. The raw material costs decreased to 11.32 Cr in March 2025 from 15.55 Cr in March 2024, contributing to a total expenditure of 13.35 Cr in March 2025, down from 17.92 Cr the previous year. Operating profit, excluding other income, improved to 0.51 Cr in March 2025, while profit before tax rose to 0.52 Cr, leading to a profit after tax of 0.41 Cr, an increase from 0.28 Cr in both March 2024 and March 2023. The company's total assets decreased to 4.56 Cr in March 2025 from 4.93 Cr in March 2024, with total liabilities also declining to 4.56 Cr. The book value per share increased to 7.01 in March 2025, reflecting a positive trend in shareholder equity, which rose to 3.14 Cr from 2.73 Cr in March 2024. Overall, while Unjha Formul experienced some volatility in sales and profits, it showed improvements in profitability metrics and shareholder value over the observed period.

Is Unjha Formul. overvalued or undervalued?

As of November 12, 2025, Unjha Formul. is considered undervalued with a PE ratio of 11.08 and a PEG ratio of 0.40, significantly outperforming peers like Sun Pharma. and Divi's Lab., and demonstrating strong long-term returns of 149.21% over three years and 250.28% over five years, despite recent underperformance year-to-date.

As of 12 November 2025, the valuation grade for Unjha Formul. has moved from very expensive to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 11.08, an EV to EBIT of 10.66, and an impressive ROE of 32.48%. <BR><BR>In comparison to its peers, Unjha Formul. stands out with a PEG ratio of 0.40, while Sun Pharma. Inds. has a PE of 35.94 and Divi's Lab. shows a staggering PE of 69.64, both categorized as expensive. The attractive valuation of Unjha Formul. is further supported by its strong performance metrics, particularly its ROCE of 16.80%. Despite recent underperformance in the YTD return compared to the Sensex, the long-term performance over 3 years and 5 years shows a remarkable return of 149.21% and 250.28%, respectively, reinforcing the attractiveness of its current valuation.

Who are the top shareholders of the Unjha Formul.?

The top shareholder of Unjha Formul is Jashodaben Shambhubhai Patel with 16.51%, followed by public shareholder Esha Mayank Patel at 1.6%. Individual investors collectively hold 56.1%, with no pledged promoter holdings or participation from mutual funds or foreign institutional investors.

The top shareholders of Unjha Formul include Jashodaben Shambhubhai Patel, who holds the highest stake at 16.51%. Following her, the highest public shareholder is Esha Mayank Patel with a holding of 1.6%. Additionally, individual investors collectively hold a significant portion of the company at 56.1%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor participation.

What is the technical trend for Unjha Formul.?

As of June 6, 2025, Unjha Formul's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bullish weekly indicators and mildly bearish monthly indicators.

As of 6 June 2025, the technical trend for Unjha Formul has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Bollinger Bands are bullish in both weekly and monthly views, suggesting potential upward movement. However, daily moving averages are mildly bearish, indicating short-term weakness. The KST shows a mildly bullish trend weekly but is mildly bearish monthly. Dow Theory indicates no trend in both weekly and monthly assessments. Overall, the indicators reflect a sideways movement with no strong bullish or bearish bias at this time.

Has Unjha Formul. declared dividend?

No Dividend History Available